Cyclacel Phar Pr Financials

Cyclacel Phar Pr (CYCCP) reported $43K in total revenue for fiscal year 2024. This represents a -89.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Cyclacel Phar Pr (CYCCP) revenue declined by 89.8% year-over-year, from $420K to $43K in fiscal year 2024.

No, Cyclacel Phar Pr (CYCCP) reported a net income of -$11.2M in fiscal year 2024, with a net profit margin of -26074.4%.

Cyclacel Phar Pr (CYCCP) reported diluted earnings per share of $-0.50 for fiscal year 2024. This represents a 92.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cyclacel Phar Pr (CYCCP) had EBITDA of -$12.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

Cyclacel Phar Pr (CYCCP) had an operating margin of -27916.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

Cyclacel Phar Pr (CYCCP) had a net profit margin of -26074.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Cyclacel Phar Pr (CYCCP) generated -$8.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Cyclacel Phar Pr (CYCCP) had $4.1M in total assets as of fiscal year 2024, including both current and long-term assets.

Cyclacel Phar Pr (CYCCP) invested $6.7M in research and development during fiscal year 2024.

Cyclacel Phar Pr (CYCCP) had 36,913 shares outstanding as of fiscal year 2024.

Cyclacel Phar Pr (CYCCP) had a current ratio of 0.59 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

Cyclacel Phar Pr (CYCCP) had a debt-to-equity ratio of -2.88 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Cyclacel Phar Pr (CYCCP) had a return on assets of -273.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Cyclacel Phar Pr (CYCCP) had $3.1M in cash against an annual operating cash burn of $8.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Cyclacel Phar Pr (CYCCP) has negative shareholder equity of -$2.2M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Cyclacel Phar Pr (CYCCP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Cyclacel Phar Pr (CYCCP) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.